Segall Bryant & Hamill LLC Sells 512 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Segall Bryant & Hamill LLC lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.4% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 36,472 shares of the company’s stock after selling 512 shares during the period. Segall Bryant & Hamill LLC’s holdings in Neurocrine Biosciences were worth $4,202,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of NBIX. Plato Investment Management Ltd boosted its position in Neurocrine Biosciences by 2,481.9% in the third quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock worth $1,263,000 after purchasing an additional 10,548 shares during the last quarter. Redwood Investment Management LLC purchased a new position in shares of Neurocrine Biosciences in the 1st quarter worth about $642,000. Tidal Investments LLC grew its position in Neurocrine Biosciences by 57.8% during the first quarter. Tidal Investments LLC now owns 9,542 shares of the company’s stock valued at $1,316,000 after buying an additional 3,497 shares during the period. KBC Group NV increased its holdings in Neurocrine Biosciences by 78.3% during the third quarter. KBC Group NV now owns 18,972 shares of the company’s stock worth $2,186,000 after buying an additional 8,332 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in Neurocrine Biosciences in the second quarter worth about $5,848,000. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $125.65 on Friday. The company’s fifty day moving average price is $118.55 and its 200-day moving average price is $132.13. The firm has a market capitalization of $12.72 billion, a price-to-earnings ratio of 33.51 and a beta of 0.35. Neurocrine Biosciences, Inc. has a one year low of $110.52 and a one year high of $157.98.

Analyst Ratings Changes

NBIX has been the subject of several research analyst reports. Royal Bank of Canada decreased their price target on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a research note on Friday, October 4th. BMO Capital Markets lowered their target price on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research note on Thursday, October 17th. Oppenheimer upped their price target on Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Barclays decreased their price objective on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a report on Monday, September 9th. Finally, StockNews.com downgraded shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.